62nd ASH Annual Meeting and Exposition: 635. Myeloproliferative Syndromes: Basic Science

Oral and Poster Abstracts
Oral

apoptosis, Biological, HSCs, Animal models, cell division, Diseases, Non-Biological, Therapies, cellular interactions, Biological Processes, DNA damage, MPN, Polycythemia vera, Technology and Procedures, Cell Lineage, epigenetics, immunotherapy, thrombocythemia, Study Population, Clinically relevant, Myeloid Malignancies, hematopoiesis, flow cytometry, inflammation, molecular interactions, pathogenesis, pathways, signal transduction

Moderators:

Linda Resar, MD, Johns Hopkins University SOM and John D. Crispino, PhD, Northwestern University

Disclosures:

No relevant conflicts of interest to declare.

1:30 PM

713

Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms

Andrew Dunbar, MD^1,2, Min Lu, PhD, MD^2,3, Mirko Farina, MD⁴^*, Young Park, BS⁵^*, Julie Yang, PhD⁶^*, Dongjoo Kim, PhD⁷^*, Abdul Karzai, BS⁵^*, Mohamed E Salama, MD⁸, Jenna Snyder, BS⁵^*, Aishwarya Krishnan, BS⁵^*, Richard P. Koche, PhD⁹^*, Rong Fan, PhD⁷^*, Ross L. Levine, MD^2,5,10 and Ronald Hoffman, MD^2,11

¹Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
²MPN Research Consortium, New York, NY
³Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
⁴Bone Marrow Transplant Unit, ASST-Spedali Civili di Brescia, Dpt of Clinical and Experimental Sciences, University of Brescia, Pavia, Pavia, Italy
⁵Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Department of Biomedical Engineering, Yale University, New Haven, CT
⁸Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
⁹Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York City, NY
¹⁰Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
¹¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

1:45 PM

714

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms

Debra Van Egeren¹^*, Javier Escabi, *¹^*, Maximilian Nguyen, *²^*, Shichen Liu³^*, Christopher R. Reilly, MD⁴^*, Sachin Patel⁵^*, Baransel Kamaz, MD⁶^*, Maria Kalyva⁷^*, Daniel J. DeAngelo, MD, PhD⁸, Ilene Galinsky⁴^*, Martha Wadleigh, MD⁴^*, Eric S. Winer, MD⁴, Marlise R Luskin, MD, MS⁴, Richard M. Stone, MD⁴, Jacqueline S. Garcia, MD⁹, Gabriela S. Hobbs, MD¹⁰, Fernando D Camargo, PhD⁵, Franziska Michor, Ph.D. #³^*, Ann Mullally, MD^4,6, Isidro Cortes-Ciriano, Ph.D. #⁷^* and Sahand Hormoz, Ph.D. #^1,3^*

¹Department of Systems Biology, Harvard Medical School, Boston
²Princeton University, Princeton
³Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
⁵Hematology/Oncology Department and Stem Cell Program, Boston Children's Hospital, Boston
⁶Division of Hematology, Brigham and Women's Hospital, Boston
⁷European Bioinformatics Institute, Cambridge, United Kingdom
⁸Department of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA
⁹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹⁰Leukemia Center, Massachusetts General Hospital, Boston, MA

2:00 PM

715

Loss of Dnmt3a Confers Resistance to Pegifnα in JAK2-V617F Mouse Model

Jan Stetka¹^*, Nils Hansen¹^*, Lucia Kubovcakova¹^*, Hui Hao-Shen¹^*, Stefan Dirnhofer²^* and Radek C. Skoda¹

¹Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
²Department of pathology, Univeristy Hospital Basel, Basel, Switzerland

2:15 PM

716

Therapeutic Potential of an Antibody Targeting the Cleaved Form of Mutant Calreticulin in Myeloproliferative Neoplasms

Yoshihiko Kihara^1,2^*, Marito Araki, PhD³^*, Misa Imai, PhD^1,2^*, Yosuke Mori, MD²^*, Mei Horino²^*, Satoko Ogata, PhD²^*, Syunpei Yoshikawa^2,4^*, Teppei Taguchi²^*, Nami Masubuchi, PhD⁵^*, Yo Mabuchi, PhD⁶^*, Yinjie Yang, PhD²^*, Yasutaka Fukuda, MD, PhD²^*, Soji Morishita, PhD³^*, Takehiro Suzuki, PhD⁷^*, Naoshi Domae, PhD⁷^*, Motoyuki Shimonaka, PhD⁴^*, Chihiro Akazawa, MD, PhD⁸^*, Akimichi Ohsaka, MD, PhD³^* and Norio Komatsu, MD, PhD²

¹Leading Center for the Development and Research of Cancer Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
²Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan
³Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan
⁴Faculty of Science, Tokyo University of Science, Tokyo, Japan
⁵Department of Hematology, Juntendo University Graduate School of Medicine, Bunkyo-Ku, TKY, Japan
⁶Department of Biochemistry and Biophysics, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo, Japan
⁷Biomolecular Characterization Unit, RIKEN Center for Sustainable Resource Science, Saitama, Japan
⁸Intractable Disease Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan

2:30 PM

717

Targeting Pleckstrin-2 for the Treatment of Myeloproliferative Neoplasms

Xu Han, PhD¹^*, Yang Mei¹^*, Gary Schiltz²^*, Rama Mishra²^*, Atul Jain²^* and Peng Ji, MD, PhD¹

¹Northwestern University, Chicago, IL
²Northwestern University, Evanston, IL

2:45 PM

718

TGF-β Signaling Contributes to the Clonal Dominance of Jak2^V617F Hematopoietic Stem/Progenitor Cells

Juo-Chin Yao¹ and Daniel C. Link, MD²

¹Washington University School of Medicine, Saint Louis, MO
²Washington University School of Medicine, St Louis, MO

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

635.O1.6 635. Myeloproliferative Syndromes: Basic Science